{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-073016","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2023-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.581032+00:00","generated_at":"2026-06-07T07:27:00.444333+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ALX Oncology amends loan agreement; extends draw period to June 30, 2024 and adds ASPEN-06 milestone","bullets":["Term A Loan draw period extended from Dec 31, 2023 to June 30, 2024.","Future Term A funding requires Phase 2 of ASPEN-06 in gastric cancer to be ongoing or have positive data.","Contingency fee of $600,000 payable to lenders if prepaid outside refinancing with Oxford and SVB.","Remaining undrawn Term A commitment reallocated to Term B and C after June 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-073016","json":"https://secwatch.observer/filing/0000950170-23-073016.json","markdown":"https://secwatch.observer/filing/0000950170-23-073016.md","text":"https://secwatch.observer/filing/0000950170-23-073016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/0000950170-23-073016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/alxo-20231222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:27:00.444333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e72396f4dae15676a2ad5a615fea0a31662e78b9","claim":"ALX ONCOLOGY HOLDINGS INC incurred term loan.","evidence_excerpt":"The Third Amendment amends the Loan Agreement to, among other things, (i) extend the draw period for the Term A Loans from December 31, 2023 to June 30, 2024","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/0000950170-23-073016-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"2fb84baeede1f52febf49e478b96035e4b2477db","claim":"ALX ONCOLOGY HOLDINGS INC amended Third Amendment to Loan and Security Agreement with Oxford Finance LLC (effective 2023-12-22).","evidence_excerpt":"On December 22, 2023, ALX Oncology Holdings Inc. (the “Company”) and its indirectly wholly-owned subsidiary, ALX Oncology Inc. (“Borrower”) entered into the Third Amendment to Loan and Security Agreement (the “Third Amendment”) by and among the Company as a guarantor, the Borrower, Oxford Finance LLC (\"Oxford\"), as collateral agent (“Agent”), and the lenders party thereto.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023073016/0000950170-23-073016-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC"},{"label":"Effective","value":"2023-12-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}